Emergent BioSolutions is on the path to finding gold with its typhoid vaccine following positive results in a Phase II trial.
The Maryland-based biopharmaceutical company is developing a single-dose oral drinkable typhoid vaccine aimed to take on Crucell’s three to four dose oral formulation and Sanofi’s injectable formulation. The global travellers market was worth $130m (€92m) in 2003, and is expected to increase to $200m by 2014.
According to the company, the typhoid vaccine candidate achieved the study endpoints for safety and immunogenicity with an overall immune response rate of greater than 50 per cent, with 95 per cent confidence.
“We are very pleased to have met the objective of this Phase II study of our typhoid vaccine candidate. This data is encouraging and indicates great promise for what would be the first single-dose, drinkable typhoid vaccine,” Emergent BioSolutions chairman and chief executive Fuad El-Hibri said.
Related posts:
- EMERGENT BIOSOLUTIONS’ TYPHOID VACCINE CANDIDATE ACHIEVES ENDPOINTS IN PHASE II CLINICAL STUDY Vaccine well tolerated and immunogenic in double-blind, placebo-controlled study in...
- Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS)...
Related posts brought to you by Yet Another Related Posts Plugin.
